针对Cdc2-Like激酶的小分子抑制剂4:进展,挑战和机遇
Yu Jiang1, Zihua Tang1, Minggao Jiang1
1West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Chemical biology & drug design
|March 17, 2025
概括
类似Cdc2的激酶4 (Clk4) 调节替代拼接,是癌症和神经退行性疾病的治疗点. 本综述详细介绍了最近的Clk4抑制剂进展,化学结构和开发策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 类似Cdc2的激酶4 (Clk4) 是CMGC激酶家族的成员,对于替代拼接至关重要.
- 替代拼接影响细胞信号传递,增殖和生存,使Clk4成为关键的治疗点.
- Clk4与神经退行性疾病,感染和癌症有关.
研究的目的:
- 审查Clk4抑制剂的最新进展,包括天然和合成化合物.
- 检查Clk4抑制剂的核心支架,功能组和有前途的化学结构.
- 探索结构-活性关系 (SARs) 和新药开发的约束模式.
主要方法:
- 关于Clk4抑制剂的最近研究的文献综述.
- 分析小分子抑制剂的化学结构和功能组.
- 检查SARs和分子结合模式.
主要成果:
- 强调了最近在开发天然和合成Clk4抑制剂方面的进展.
- 确定了Clk4抑制的关键化学支架和功能组.
- SAR和结合模式为抑制剂设计提供了洞察力.
结论:
- Clk4 抑制剂在治疗癌症和神经退行性疾病方面表现有前途.
- 了解SAR和结合方式对于开发选择性Clk4抑制剂至关重要.
- 需要进一步的研究来克服Clk4向药物开发的挑战.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Anaphase Promoting Complex
2.8K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K
Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


